{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T20:51:18Z","timestamp":1780087878106,"version":"3.54.0"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T00:00:00Z","timestamp":1592870400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology Case Reports"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.ajoc.2020.100799","type":"journal-article","created":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T13:21:47Z","timestamp":1593177707000},"page":"100799","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Progressive choroidal thinning (leptochoroid) and fundus depigmentation associated with checkpoint inhibitors"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6548-6879","authenticated-orcid":false,"given":"Julia","family":"Canestraro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5657-3930","authenticated-orcid":false,"given":"Korey A.","family":"Jaben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jedd D.","family":"Wolchok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Abramson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine H.","family":"Francis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajoc.2020.100799_bib1","series-title":"The Basics of Cancer Immunotherapy","first-page":"95","article-title":"Next generation immunotherapy in lymphoma: checkpoint blockade, chimeric antigen receptor T cells, and beyond","author":"Villasboas","year":"2018"},{"key":"10.1016\/j.ajoc.2020.100799_bib2","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/IAE.0000000000002181","article-title":"Checkpoint inhibitor immune therapy, systemic indications and ophthalmic side effects","volume":"38","author":"Dalvin","year":"2018","journal-title":"Retina"},{"key":"10.1016\/j.ajoc.2020.100799_bib3","author":"Liu"},{"key":"10.1016\/j.ajoc.2020.100799_bib4","first-page":"1","article-title":"Peripheral leptochoroid: clinical and anatomical findings","author":"Francis","year":"2017","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ajoc.2020.100799_bib5","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10792-014-9962-4","article-title":"Choroidal thickness in relation to sex, age, refractive error, and axial length in healthy Turkish subjects","volume":"35","author":"Tuncer","year":"2015","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.ajoc.2020.100799_bib6","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/CJI.0000000000000066","article-title":"Vogt-Koyanagi-Harada-like syndrome after CTLA-4 inhibition with ipilimumab for metastatic melanoma","volume":"38","author":"Crosson","year":"2015","journal-title":"J Immunother"},{"issue":"8","key":"10.1016\/j.ajoc.2020.100799_bib7","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1001\/jamaophthalmol.2015.1128","article-title":"Bilateral choroidopathy and serous retinal detachments during ipilimumab treatment for cutaneous melanoma","volume":"133","author":"Mantopoulos","year":"2015","journal-title":"JAMA Ophthalmology"},{"issue":"4","key":"10.1016\/j.ajoc.2020.100799_bib8","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/ICB.0b013e31824f7130","article-title":"Bilateral drug (Ipilimumab)-Induced vitritis, choroiditis, and serous retinal detachments suggestive of vogt-koyanagi-harada syndrome","volume":"6","author":"Wong","year":"2012","journal-title":"Retin Cases Brief Rep"},{"key":"10.1016\/j.ajoc.2020.100799_bib9","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/CJI.0000000000000154","article-title":"Vogt-Koyanagi-Harada-like syndrome complicating pembrolizumab treatment for metastatic melanoma","volume":"40","author":"Bricout","year":"2017","journal-title":"J Immunother"},{"key":"10.1016\/j.ajoc.2020.100799_bib10","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/sj.eye.6701351","article-title":"Cutaneous vitiligo associated with choroidal hypopigmentation","volume":"18","author":"Vingerling","year":"2004","journal-title":"Eye"},{"key":"10.1016\/j.ajoc.2020.100799_bib11","series-title":"Duane's Ophthalmology","first-page":"1","article-title":"Prenatal development of the eye and its adnexa","author":"Cook","year":"1991"}],"container-title":["American Journal of Ophthalmology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451993620301353?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451993620301353?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T14:58:16Z","timestamp":1762527496000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2451993620301353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":11,"alternative-id":["S2451993620301353"],"URL":"https:\/\/doi.org\/10.1016\/j.ajoc.2020.100799","relation":{},"ISSN":["2451-9936"],"issn-type":[{"value":"2451-9936","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Progressive choroidal thinning (leptochoroid) and fundus depigmentation associated with checkpoint inhibitors","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajoc.2020.100799","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100799"}}